Core Viewpoint - Weikang Pharmaceutical (300878.SZ) expects a net profit attributable to shareholders of the listed company to be between -245 million to -170 million yuan for 2025, representing a year-on-year decline of 66.18% to 15.31% [1] Group 1: Financial Performance - The company has a large scale of fixed assets but low capacity utilization, leading to significant depreciation expenses that negatively impact profits [1] - The company has recognized an impairment provision for fixed assets amounting to 45.55 million yuan [1] - The sales price of the company's products has decreased, and sales volume did not meet expectations, resulting in a decline in both operating revenue and gross margin [1] Group 2: Inventory Management - Some inventory is approaching its expiration date, prompting the company to recognize an inventory impairment provision of 30.39 million yuan [1]
维康药业(300878.SZ)：预计2025年净亏损1.7亿元-2.45亿元